Human ebola virus species and compositions and methods thereof

Patent metadata

Field	Value
Publication number	US-10428314-B2
Application number	US-201715688421-A
Country	US
Kind code	B2
Filing date	Aug 28, 2017
Priority date	Oct 24, 2008
Publication date	Oct 1, 2019
Grant date	Oct 1, 2019

Abstract

Compositions and methods including and related to the Ebola Bundibugyo virus (EboBun) are provided. Compositions are provided that are operable as immunogens to elicit and immune response or protection from EboBun challenge in a subject such as a primate. Inventive methods are directed to detection and treatment of EboBun infection.

First claim

It is claimed:

1. A vector, comprising a heterologous nucleic acid molecule encoding at least 70 contiguous residues of the amino acid sequence of SEQ ID NO: 9 (GP).

2. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes at least 80 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

3. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes of at least 100 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

4. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes at least 200 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

5. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes at least 300 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

6. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes at least 400 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

7. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes at least 500 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

8. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes at least 600 contiguous residues of the amino acid sequence of SEQ ID NO: 9.

9. The vector of claim 1 , wherein the heterologous nucleic acid molecule encodes the amino acid sequence of SEQ ID NO: 9.

10. The vector of claim 1 , wherein the vector is a recombinant vesicular stomatitis virus vector.

11. A method of inducing an immune response in a subject, comprising:
administering an effective amount of the vector of claim 1 to the subject to induce the immune response.

12. The method of claim 11 , wherein the immune response inhibits Ebola virus infection in the subject.

13. A vector, comprising a heterologous nucleic acid molecule encoding a polypeptide comprising an amino acid sequence at least 75% identical to SEQ ID NO: 9.

14. The vector of claim 13 , wherein the polypeptide comprising an amino acid sequence at least 80% identical to SEQ ID NO: 9.

15. The vector of claim 13 , wherein the polypeptide comprising an amino acid sequence at least 85% identical to SEQ ID NO: 9.

16. The vector of claim 13 , wherein the polypeptide comprising an amino acid sequence at least 90% identical to SEQ ID NO: 9.

17. The vector of claim 13 , wherein the polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 9.

18. The vector of claim 13 , wherein the vector is a recombinant vesicular stomatitis virus vector.

19. A method of inducing an immune response in a subject, comprising:
administering an effective amount of the vector of claim 13 to the subject to induce the immune response.

20. The method of claim 19 , wherein the immune response inhibits Ebola virus infection in the subject.

Assignees

• Us Health

Inventors

• Towner Jonathan S
• Nichol Stuart T
• Comer James A
• Ksiazek Thomas G
• Rollin Pierre E

Classifications

• C07K2317/76

  Antagonist effect on antigen, e.g. neutralization or inhibition of binding · CPC title

• G01N2333/08

  RNA viruses · CPC title

• A61K2039/5254

  avirulent or attenuated · CPC title

• A61K2039/53

  DNA (RNA) vaccination · CPC title

• C12N2760/14134

  Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title